electroCore’s non invasive vagus nerve stimulation therapy for the
prevention and treatment of cluster headache and migraine was reviewed
at both the AHS Annual Scottsdale Headache Symposium (Nov 21st
to 24th) and the NANS meeting this weekend (Dec 5th to 8th).
... read more
Laboratory Corporation of America® Holdings (LabCorp®)
(NYSE: LH) announced today the launch of a new oncology panel on its
next generation sequencing (NGS) platform. The IntelliGEN assay improves
sensitivity and detection rates for somatic mutations in cancer,
assessing approximately 2600 mutations within 50 oncogenes/tumor
... read more
The way people share their experience with local companies has changed. If you have made a purchase from Amazon.com, peer reviews have most likely influenced your purchase decision. This is now happening with local businesses. The communities taking advantage of this are grabbing the lion's share of prospects. In fact, Internet reviews are trusted by 70% of consumer opinions - more than all types of advertising, including websites, radio, TV, newspaper and magazines.
Kevin Williams, President of SeniorMarketing.com, has been invited ... read more
CARLSBAD, CA -- (Marketwired) -- 12/09/13 -- International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies announces significant advancement in human induced pluripotent stem cells (iPS) derivation with novel protein-based reprogramming method.
ISCO's biologists have developed a fundamentally new method that both successfully enhances the efficiency of the reprogramming process using specific proteins called transducible transcription factors (TTF) and avoids the use of viruses. ISCO has now shown that this TTF-iPS technology ... read more
Inc., today announced that it has been invited to participate in the
world's first G8 Dementia Summit, hosted by the British Prime Minister,
David Cameron, and Health Secretary, Jeremy Hunt. Alzheon’s Chief
Executive Officer, Martin Tolar, will be among the industry leaders in
... read more
(NASDAQ: OVAS), a life sciences company focused on the discovery,
development and commercialization of new treatments for infertility,
announced today the appointment of Michelle Dipp, M.D., Ph.D., Chief
Executive Officer of OvaScience, to the Biotechnology Industry
Organization’s (BIO) Emerging ... read more
Raytheon BBN Technologies and GrammaTech, Inc. are collaborating on a $4.8 million contract award under the Defense Advanced Research Projects Agency's VET program. Raytheon BBN Technologies is a wholly owned subsidiary of Raytheon Company (NYSE: RTN).
The VET (Vetting Commodity IT Software and Firmware) program seeks to help U.S. government agencies address the threat of malicious code and hidden "backdoor" access in commodity IT devices. Mobile phones, network routers, computer workstations and other networked devices can be secretly modified to ... read more
Holding the number one spot in the world for the second consecutive year, a Northrop Grumman Corporation (NYSE: NOC) team of cyber engineers won the overall "grand champion" title in the Defense Cyber Crime Center's (DC3's) eighth annual Digital Forensics Challenge.
The global challenge is a call to the digital forensics community to pioneer new investigative tools, techniques and methodologies to address the dynamic cyber threat. The challenge encourages innovation from a broad range of individuals, teams and ... read more
STS Health(TM) has announced the availability of FluNada® a non-prescription, homeopathic throat and nasal spray formulated to provide relief from cold and flu-like symptoms, in more than 5,000 retail pharmacies. FluNada is the only remedy for cold and flu-like symptoms that coats both the throat and nasal pathways, where most viruses enter the body. It is designed to inhibit replication of viruses. The non-drowsy formula contains natural ingredients to relieve runny or blocked nose, sore throat, cough, and body aches ... read more
Inc. (NASDAQ: IMGN), a biotechnology
company that develops targeted, antibody-based anticancer therapeutics,
today announced the first clinical findings with SAR650984 reported in
an oral presentation at the ASH annual meeting. The data are from an
ongoing Phase I trial ... read more
Medicine today announced new data demonstrating that its fully
informative genomic profile for hematologic cancers, FoundationOne™
Heme, can be performed in routine clinical cancer specimens to identify
all classes of genomic alterations, including gene fusions, across
hundreds of genes ... read more
The finest, most skilled researchers from around the world are racing toward the solution for the most prevalent disease known to man ... the problem of aging. For decades, conventional wisdom spouted by family doctors and general practitioners has said that one should seek to grow old gracefully. One should just accept that the passage of time is going to result in a certain debilitation of the human body. Reading through the new website, HGHInjections.com just published by Kingsberg Medical, ... read more
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that payers are increasingly adopting value-based pricing as a way to focus their limited pharmaceutical budgets on drugs that meet genuine clinical needs and better reward manufacturers for developing such medicines. Value-based pricing is a method of pricing medicines based on willingness to pay or the perceived additional benefit of new drugs relative to established comparator therapies.
The Strategic Insights report entitled, Key Trends ... read more
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed gastroenterologists across the EU5 (France, Germany, Italy, Spain and the United Kingdom) anticipate prescribing Gilead's sofosbuvir to approximately 20 percent of their hepatitis C virus genotype 1 (HCV-1) patients and Janssen/Medivir's simeprevir to approximately 7 percent of these patients by the end of 2015. Surveyed specialists also indicated that they expect to prescribe sofosbuvir-based regimens to more than one-third of their ... read more
NMI Holdings, Inc., (NASDAQ: NMIH) the parent company of National Mortgage Insurance Corporation (National MI) announces that National MI has been named to the Web Marketing Association's list of "Outstanding Websites" for its site, www.nationalmi.com. Since 1997, the WebAwards annual competition has set industry benchmarks for the best web sites around the world. National MI was honored as one of the best websites in the insurance industry.
(Logo: http://photos.prnewswire.com/prnh/20130731/FL56494LOGO )
"We are thrilled to receive this award," said ... read more
Life Technologies Corporation today announced a partnership with the Canadian Centre for DNA Barcoding in support of the Centre's International Barcode of Life (iBOL) project, a global biodiversity study that will genetically sequence and catalogue 5 million specimens and 500,000 species by late 2015.
DNA-based approaches are playing a crucial role in helping scientists to accelerate the identification of the tens-of-millions of species on Earth and the role they play in maintaining the planet's ecosystem. The partnership will enable iBOL project ... read more
Health, the leading provider of electronic Clinical Outcome
Assessment Solutions (eCOA) for the life sciences industry, was named in
the 2013 edition of Deloitte’s Technology Fast 500™. This is the second
year in a row that CRF Health has been ranked as one of the ... read more
According to the Centers for Disease Control and Prevention (CDC),
diabetes affects 25.8 million Americans. If trends continue, more than a
third of the country will have the disease by 2050. In 2012, the
estimated total cost of diagnosed diabetes in the United States was $245
... read more
Inc. (GMI) today announced that the company and its collaborators
highlighted its novel glycomimetic drug candidate, E-selectin antagonist GMI-1271,
during an oral presentation and poster session at the 2013
American Society of Hematology (ASH) Annual Meeting and Exposition.
GMI-1271 ... read more
Neuraltus Pharmaceuticals, Inc. announced today that promising efficacy results of the Company's Phase 2 clinical program of NP001 for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease) were highlighted in an oral presentation at the 24th International Symposium on ALS/MND, held in Milan, Italy. Study efficacy results demonstrated positive trends in the ability of NP001 to slow the rate of disease progression, ranging from 13 to 19% in multiple parameters of clinical benefit, although these pre-defined ... read more